Back to Browse Journals » Neuropsychiatric Disease and Treatment » Volume 4 » Issue 5

Augmentation treatment in major depressive disorder: focus on aripiprazole

Authors J Craig Nelson, Andrei Pikalov, Robert M Berman

Published Date August 2008 Volume 2008:4(5) Pages 937—948

DOI http://dx.doi.org/10.2147/NDT.S3369

Published 11 August 2008

J Craig Nelson1, Andrei Pikalov2, Robert M Berman3

1University of California San Francisco, San Francisco, California, USA; 2Otsuka Pharmaceutical Inc., Rockville, MD, USA; 3Bristol-Myers Squibb, Wallingford, CT, USA

Abstract: Major depressive disorder (MDD) is a disabling psychiatric condition for which effective treatment remains an outstanding need. Antidepressants are currently the mainstay of treatment for depression; however, almost two-thirds of patients will fail to achieve remission with initial treatment. As a result, a range of augmentation and combination strategies have been used in order to improve outcomes for patients. Despite the popularity of these approaches, limited data from double-blind, randomized, placebo-controlled studies are available to allow clinicians to determine which are the most effective augmentation options or which patients are most likely to respond to which options. Recently, evidence has shown that adjunctive therapy with atypical antipsychotics has the potential for beneficial antidepressant effects in the absence of psychotic symptoms. In particular, aripiprazole has shown efficacy as an augmentation option with standard antidepressant therapy in two, large, randomized, double-blind studies. Based on these efficacy and safety data, aripiprazole was recently approved by the FDA as adjunctive therapy for MDD. The availability of this new treatment option should allow more patients with MDD to achieve remission and, ultimately, long-term, successful outcomes.

Keywords: major depression, antipsychotic, mood disorder, aripiprazole

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other article by this author:

Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder

Berman R, Thase M, Trivedi M, Hazel JA, Marler S, McQuade R, Carson W, Baker R, Marcus R

Neuropsychiatric Disease and Treatment 2011, 7:303-312

Published Date: 24 May 2011

Readers of this article also read:

Endothelial keratoplasty with infant donor tissue

Kobayashi A, Yokogawa H, Yamazaki N, Masaki T, Sugiyama K

Clinical Ophthalmology 2014, 8:1827-1830

Published Date: 11 September 2014

COMT Val158Met, but not BDNF Val66Met, is associated with white matter abnormalities of the temporal lobe in patients with first-episode, treatment-naïve major depressive disorder: a diffusion tensor imaging study

Hayashi K, Yoshimura R, Kakeda S, Kishi T, Abe O, Umene-Nakano W, Katsuki A, Hori H, Ikenouchi-Sugita A, Watanabe K, Ide S, Ueda I, Moriya J, Iwata N, Korogi Y, Kubicki M, Nakamura J

Neuropsychiatric Disease and Treatment 2014, 10:1183-1190

Published Date: 25 June 2014

Radiation dose to the nodal regions during prone versus supine breast irradiation

Csenki M, Újhidy D, Cserháti A, Kahán Z, Varga Z

Therapeutics and Clinical Risk Management 2014, 10:367-372

Published Date: 21 May 2014

A novel polyethyleneimine-coated adeno-associated virus-like particle formulation for efficient siRNA delivery in breast cancer therapy: preparation and in vitro analysis

Shao W, Paul A, Abbasi S, Chahal PS, Mena JA, Montes J, Kamen A, Prakash S

International Journal of Nanomedicine 2012, 7:1575-1586

Published Date: 23 March 2012

Antibiofilm surface functionalization of catheters by magnesium fluoride nanoparticles

Lellouche J, Friedman A, Lahmi R, Gedanken A, Banin E

International Journal of Nanomedicine 2012, 7:1175-1188

Published Date: 1 March 2012

Corrigendum

Sailasuta N, Harris K, Tran T, Ross B

Neuropsychiatric Disease and Treatment 2011, 7:707-708

Published Date: 25 November 2011

Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia

Louzã M, Elkis H, Ruschel S, de Oliveira IR, Bressan RA, Belmonte-de-Abreu P, Grabowski H, Appolinário JC

Neuropsychiatric Disease and Treatment 2011, 7:391-398

Published Date: 23 June 2011

Comparison of preference and safety of powder and liquid lactulose in adult patients with chronic constipation

Charles F Barish, Bryan Voss, Byron Kaelin

Clinical and Experimental Gastroenterology 2010, 3:153-158

Published Date: 19 October 2010

Erratum

RA Kurt, K Gündüz

Clinical Ophthalmology 2010, 4:981-982

Published Date: 6 September 2010

Development of a functional HTS assay for the APJ receptor

Angela Giddings, Scott Runyon, James Thomas, et al

International Journal of High Throughput Screening 2010, 1:39-47

Published Date: 19 April 2010